Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inosine pranobex (Newport Pharmaceuticals Limited)
- Development stage
- Unknown
- Lead developer
- Newport Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Inosine pranobex is a synthetic small-molecule drug that combines inosine with dimepranol acedoben (a salt of acetamidobenzoic acid and dimethylaminoisopropanol) in a 1:3 molar ratio. It functions primarily as an immunomodulator and indirect antiviral agent. Rather than targeting viral particles directly, it enhances the host's immune response by stimulating T-lymphocyte proliferation, increasing natural killer (NK) cell activity, and promoting the production of pro-inflammatory cytokines such as interleukin-1 and interleukin-2. It is also described as an analog of thymus hormones. The drug has been approved in various jurisdictions for the treatment of viral infections including herpes simplex, subacute sclerosing panencephalitis (SSPE), and respiratory viral infections, and has been investigated for managing immunodeficiency in patients with HIV/AIDS.
- Brand names
- IsoprinosineImunovirViruxanDelimmunInosiplex
- Other names
- inosine acedoben dimepranolmethisoprinolinosiplex
02
Targets
Viral RNA-dependent RNA polymerase complex (RdRp complex)
Beyond the preview
Go deeper on inosine pranobex (Newport Pharmaceuticals Limited).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inosine pranobex (Newport Pharmaceuticals Limited).